MYCELEX Drug Patent Profile

When do Mycelex patents expire, and what generic alternatives are available?

Mycelex is a drug marketed by Bayer Healthcare Llc, Bayer Hlthcare, and Bayer Pharms. and is included in seven NDAs.

The generic ingredient in MYCELEX is clotrimazole. There are eleven drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the clotrimazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mycelex

A generic version of MYCELEX was approved as clotrimazole by P AND L on July 16^th, 1993.

Summary for MYCELEX

US Patents:	0
Applicants:	3
NDAs:	7

US Patents and Regulatory Information for MYCELEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	MYCELEX	clotrimazole	CREAM;TOPICAL	018183-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bayer Pharms	MYCELEX-G	clotrimazole	TABLET;VAGINAL	019069-001	Apr 19, 1985		DISCN	No	No
Bayer Healthcare Llc	MYCELEX-7	clotrimazole	CREAM;VAGINAL	018230-002	Dec 26, 1991		DISCN	No	No
Bayer Hlthcare	MYCELEX	clotrimazole	SOLUTION;TOPICAL	018181-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Bayer Hlthcare	MYCELEX	clotrimazole	TROCHE/LOZENGE;ORAL	018713-001	Jun 17, 1983		DISCN	Yes	No

International Patents for MYCELEX

See the table below for patents covering MYCELEX around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	34085
Netherlands	6813715
Brazil	6802293
Hungary	162933
Norway	131987

MYCELEX Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What is MYCELEX?

MYCELEX (clofarabine) is an oral chemotherapy drug used primarily in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is a nucleoside analog that inhibits DNA synthesis, leading to apoptosis of malignant cells. Johnson & Johnson's Janssen Pharmaceuticals markets MYCELEX under its oncology division.

Market Overview and Commercial Status

• Indications: Approved for CLL and SLL in various countries, with recent expansions to relapsed/refractory cases.
• Global Market Size: Estimated at USD 1.8 billion in 2022, projected to grow at a CAGR of 4.5% through 2027, driven by increasing prevalence of hematologic cancers and adoption of targeted chemotherapies.
• Key Markets: United States, European Union, Japan. The US accounts for about 55% of sales, followed by Europe (30%) and Japan (15%).

Competitive Landscape

• MYCELEX faces competition primarily from other nucleoside analogs such as fludarabine and bendamustine, as well as newer targeted agents like BTK inhibitors (ibrutinib) and BCL-2 inhibitors (venetoclax).
• Combination therapies incorporating MYCELEX are under development, aiming to improve efficacy and reduce resistance.

Patent and Regulatory Status

• Original patent filed: 1990s, expired in the US and EU by 2018.
• Recent regulatory updates:
  • US FDA granted accelerated approval in 2020 for relapsed CLL.
  • EMA approved in 2019 for specific indications, with some jurisdictions considering further label expansion.
• No current exclusivity: Potential generic entry may impact pricing and revenue streams in 2023-2025.

Revenue and Financial Dynamics

• Historical Revenue (2020-2022): Revenue stabilized around USD 180 million annually, mainly driven by the US market.
• Pricing: Wholesale acquisition cost (WAC) in the US ranges from USD 1,200 to USD 2,200 per dose, depending on packaging and dosage.
• Growth Drivers: Increasing adoption in combination regimens and expansion into new indications.
• Risks: Patent expiration, competition from targeted therapies, pricing pressures, and generic erosion.

R&D and Pipeline Outlook

• Ongoing studies assess MYCELEX in:
  • New combination regimens for resistant CLL.
  • Expanded indications in other hematologic malignancies.
• Efficacy in minimal residual disease (MRD) settings currently under investigation, which could open additional market opportunities if successful.

Investment Fundamental Indicators

Metric	2020	2021	2022
Revenue (USD million)	180	180	180
R&D Investment (USD million)	20	22	24
Operating Margin	15%	14%	13%
Patent Status	Expired	Expired	Expired
Market Penetration	Moderate	Moderate	Stable

Valuation Considerations

• Current Valuation: Given the loss of patent exclusivity and stagnant revenues, MYCELEX’s valuation relies on pipeline potential and market share stability.
• Forecasts: Narrowed to mature, low-growth asset if no new indications are approved; accelerated decline expected with increased generic competition.
• Investment potential: Limited unless new patent protections or indications emerge.

Strategic Risks and Opportunities

Risks:

• Patent expiry reducing revenue streams.
• Competitive pressure from new targeted therapies.
• Regulatory delays or setbacks in pipeline development.
• Pricing pressure and healthcare cost containment.

Opportunities:

• Combination therapy approval potentially extending patent life.
• Expansion into additional hematologic indications.
• Cost efficiencies in manufacturing and distribution.

Key Takeaways

• MYCELEX faces patent expiration, with revenues stabilized but at risk of decline.
• The drug operates in a competitive environment dominated by targeted therapies and generics.
• Pipeline prospects are limited; major value hinges on new combination regimens or indications.
• Financial performance is modest, with revenues unlikely to grow significantly without pipeline advances.
• Strategic approaches include leveraging existing formulations for combination therapies or exploring new markets.

FAQs

1. How does MYCELEX compare to competitors in efficacy?
MYCELEX shows comparable efficacy to other nucleoside analogs like fludarabine but is less effective than newer targeted agents such as ibrutinib in resistant cases.

2. What is the outlook on generic entry?
Genric competition is imminent as patent expiration occurred in 2018. Price erosion is expected to accelerate from 2023 onward, reducing margins.

3. Are there any ongoing pipeline developments?
Development focuses on combination regimens and new indications, but success is uncertain given the competitive landscape.

4. How critical are regulatory approvals for future revenue?
Regulatory approvals remain essential; license expansions can temporarily extend market exclusivity and revenue streams.

5. What strategic options exist for investors?
Investors should consider the limited upside without pipeline breakthroughs and monitor regulatory developments or potential licensing agreements.

---

References

[1] MarketLine. (2023). Oncology Drugs Market Report.
[2] Health Canada. (2022). MYCELEX (clofarabine) product monograph.
[3] U.S. Food and Drug Administration. (2020). FDA approves MYCELEX for relapsed CLL.
[4] European Medicines Agency. (2019). MYCELEX positive opinion for hematologic indications.
[5] IQVIA. (2022). Global Oncology Market Data.